UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT PURSUANT
TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): June 18, 2018
|
SECOND SIGHT MEDICAL PRODUCTS, INC. |
|||||
|
(Exact Name of Registrant as Specified in Its Charter) |
|||||
|
|
|||||
|
California |
|||||
|
(State or Other Jurisdiction of Incorporation) |
|||||
|
|
|||||
|
|
333-198073 |
|
|
02-0692322 |
|
|
(Commission File Number) |
(IRS Employer Identification No.) |
||||
|
|
|
||||
|
|
12744 San Fernando Road, Suite 400 |
|
|||
|
(Address of Principal Executive Offices) |
|||||
|
|
|||||
|
(818) 833-5000 |
|||||
|
(Registrant's Telephone Number, Including Area Code) |
|||||
|
(Former Name or Former Address, if Changed Since Last Report) |
|||||
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
ITEM 8.01 Other Items
Consulting Agreement with Robert J. Greenberg, M.D. Ph. D.
On June 18, 2018, the Company entered into a consulting agreement with Dr. Robert J. Greenberg, a former Chief Executive Officer and Chairman of the Board of the Company. Under this agreement Dr. Greenberg has agreed to provide the Company from time to time, as requested, consulting and advisory services that relate to the design and clinical study for the visual prosthetics now under development at the Company. The agreement extends through April 2, 2019 but may be terminated by either party at any time on giving seven days written notice to the other. A copy of the consulting agreement is attached to this Report as Exhibit 99.1 and is incorporated herein by this reference.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
|
Exhibit No. |
Description |
|
99.1 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: June 21, 2018
SECOND SIGHT MEDICAL PRODUCTS, INC.
| /s/ Jonathan Will McGuire |
By: Jonathan Will McGuire
Chief Executive Officer
-2-